Skip to main content

Table 5 Median dose and relative confidential interval values of EGFR/HER2 pathway inhibitors on BTC cell lines.

From: Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas

 

TFK1

EGI-1

HuH28

TGBC1-TKB

Erlotinib Dm (CI)

2.59 μM

5.72 μM

>10

>10

 

(0.17-3.46)

(1.9-7.5)

  

Gefitinib Dm (CI)

1.8 μM

2.48 μM

>10

>10

 

(1.1-2.9)

(1.5-4.03)

  

Lapatinib Dm (CI)

5.25 μM

4.02 μM

2.02 μM

>10

 

(1.01-7.2)

(1.01-5.9)

(1.2-4.62)

 

Sorafenib Dm (CI)

6.2 μM

2.06 μM

>10

5.9 μM

 

(3.1-12.4)

(0.45-9.37)

 

(3.8-7.9)

Everolimus Dm (CI)

0.20 μM

0.5 μM

>10

0.42 μM

 

(0.02-1.76)

(0.1-1.5)

 

(0.33-0.54)

  1. The Median doses (Dm) and relative confidential interval (CI) of targeted therapies which affected 50% proliferation on the four cell lines (TFK1, EGI-1, HuH28, and TGBC1-TKB) were calculated after 72 hrs of drug treatment.